Search
Congress Materials
RELISTOR®
(methylnaltrexone bromide) 8 mg/12 mg subcutaneous injection
Subcutaneous injection
Society of Hospital Medicine (SHM) Converge—March 26–29, 2023, Austin, TX
Impact of subgroups on methylnaltrexone efficacy/safety in advanced illness [encore]
Mehta N, et al.
Society of Hospital Medicine (SHM) 2022—April 7–10, 2022, Nashville, TN
Approved opioid-induced constipation medication use in emergency department patients with opioid-induced constipation
Peacock WF, et al.
Efficacy of methylnaltrexone in patients with advanced illness and opioid induced-constipation refractory to conventional laxatives: impact of baseline laxative use
Sayuk G, et al.
Attenuation of adverse events over 7 doses in methylnaltrexone-treated patients with opioid-induced constipation and severe medical illness
Sayuk G, et al.
Society of Critical Care Medicine (SCCM) Critical Care Congress 2022—February 6–9, 2022, San Juan, Puerto Rico
Naloxone versus methylnaltrexone for opioid-induced constipation in critically ill patients
Habeeb E, et al.
American College of Gastroenterology (ACG) Annual Scientific Meeting 2021—October 22–27, 2021, Las Vegas, NV
A pooled analysis of the efficacy and safety of methylnaltrexone for opioid-induced constipation in patients with severe medical illness: the impact of baseline opioid equivalent dose
Sayuk GS, et al.
Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO) Annual Meeting on Supportive Care in Cancer—June 24–26, 2021, Virtual
Rescue-free laxation response with methylnaltrexone treatment in cancer patients with opioid-induced constipation: the impact of baseline ECOG status
Boniol S, et al.
Digestive Disease Week (DDW) 2020—May 2–5, 2020, Virtual
Cumulative laxation response with methylnaltrexone: implications for hospitalized patients with advanced illness and opioid-induced constipation [Encore]
Farchadi D, et al.
Attrition of methylnaltrexone treatment-emergent adverse events in patients with chronic noncancer pain and opioid-induced constipation [Encore]
Mehta N, et al.
4th Meeting of the Federation of Neurogastroenterology and Motility—March 25–28, 2020, Adelaide, Australia
PAMORAs result in clinically significant improvement in spontaneous and complete spontaneous bowel movements with low risk of side effects in patients with opioid induced constipation: systematic review and meta-analysis
Vijayvargiya P, et al.
American Academy of Hospice and Palliative Medicine (AAHPM): State of the Science in Hospice and Palliative Care 2020—March 20–22, 2020, Meeting Cancelled
Prevention and treatment of chronic and opioid-induced constipation in patients with cancer: a systematic review and meta-analysis
Ginex P, et al.
PAINWeek 2019—September 3–7, 2019, Las Vegas, NV
Attrition of treatment-emergent adverse events by methylnaltrexone in patients with chronic noncancer pain and opioid-induced constipation
Mehta N, et al.
Treatment with methylnaltrexone in patients with opioid-induced constipation with or without active cancer: effects of the initial dose based on 3 pooled clinical studies
Chamberlain B, et al.
Digestive Disease Week (DDW) 2019—May 18–21, 2019, San Diego, CA
The influence of age on central nervous system effects of methylnaltrexone in patients with opioid-induced constipation: a pooled analysis of 4 clinical trials
Liao S, et al.
Efficacy variables in cancer versus noncancer patients treated with methylnaltrexone or placebo: an analysis of two placebo-controlled studies
Chamberlain BH, et al.
International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2017—October 15–18, 2017, Yokohama, Japan
Effectiveness of methylnaltrexone bromide in opioid-induced constipation in advanced NSCLC patients
Dimitroulis I, et al.
American College of Gastroenterology (ACG) Annual Scientific Meeting 2017—October 13–18, 2017, Orlando, FL
Effectiveness of various treatment agents for opioid-induced constipation: a meta-analysis
Saleem R, et al.
American Pain Society (APS) Annual Scientific Meeting 2017—May 17–20, 2017, Pittsburgh, PA
Oral methylnaltrexone for adults with chronic noncancer pain and opioid-induced constipation (OIC): timing and characterization of clinical symptoms do not suggest opioid withdrawal with daily treatment
Rauck R, et al.
Digestive Disease Week (DDW) 2017—May 6–9, 2017, Chicago, IL
Use of methylnaltrexone in cancer patients with peritoneal carcinomatosis
Nelson KK, et al.
PAINWeek 2016—September 6–10, 2016, Las Vegas, NV
Peripherally acting mu-opioid receptor antagonists (PAMORAs) for constipation associated with chronic opioid therapy
Pergolizzi JV, et al.
Society of Hospital Medicine (SHM) 2015—March 29–April 1, 2015, National Harbor, MD
Efficacy and safety of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain: a placebo crossover analysis [Encore]
Viscusi ER, et al.
Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension
Bull J, et al.
American Pain Society (APS) Annual Scientific Meeting 2013—May 8–11, 2013, New Orleans, LA
Efficacy and safety of subcutaneous methylnaltrexone in advanced illness patients with opioid-induced constipation: a responder analysis
Nalamachu S, et al.
Effect of subcutaneous methylnaltrexone on patient-reported outcomes in advanced illness patients with opioid-induced constipation
Peppin J, et al.
Neurogastroenterology and Motility 2011—September 16–18, 2011, St. Louis, MO
Subcutaneous methylnaltrexone provides long-term laxation in patients with chronic non-malignant pain and opioid-induced constipation [abstract 153; page 44]
Webster LR, et al.
Search
*Required field.
Select a product*
Select a therapeutic area*
Enter keyword(s)